Cargando…
Chronological improvement in precision oncology implementation in Japan
In Japan, comprehensive genomic profiling (CGP) tests for refractory cancer patients have been approved since June 2019, under the requirement that all cases undergoing CGP tests are annotated by the molecular tumor board (MTB) at each government‐designated hospital. To investigate improvement in pr...
Autores principales: | Sunami, Kuniko, Naito, Yoichi, Komine, Keigo, Amano, Toraji, Ennishi, Daisuke, Imai, Mitsuho, Kage, Hidenori, Kanai, Masashi, Kenmotsu, Hirotsugu, Koyama, Takafumi, Maeda, Takahiro, Morita, Sachi, Sakai, Daisuke, Kohsaka, Shinji, Tsuchihara, Katsuya, Saigusa, Yusuke, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633287/ https://www.ncbi.nlm.nih.gov/pubmed/35976133 http://dx.doi.org/10.1111/cas.15517 |
Ejemplares similares
-
The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan
por: Sunami, Kuniko, et al.
Publicado: (2021) -
Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors
por: Imai, Mitsuho, et al.
Publicado: (2022) -
Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan
por: Naito, Yoichi, et al.
Publicado: (2022) -
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence
por: Sunami, Kuniko, et al.
Publicado: (2023) -
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA
por: Sunami, Kuniko, et al.
Publicado: (2021)